temozolomide,Ibrutinib,Rituximab,Doxorubicin,Dexamethasone
abbvie,janssen
['lymsm', 'pcnsl']
teddi-r in pcnsl #17icml
- adapted to ibr response
- 50 pts (30% age&gt;70, 56% synchronous, most r/r)
- no aspergillus (antifungals), 30% hfs with doxil
- 1-yr pfs 38%, os 60%
can be given outpatient in sick/older pts. os high b/c viper off protocol after pd. #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈